ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Options Flow

Live Options Flow

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
S&P TSX Capped Composite...
36.44
0.72%
US Tech 100
19,294.00
1.50%
S&P 500
5,564.14
1.07%
US Dollar vs CAD
1.37507
-0.16%
Bitcoin
67,530.24
-0.92%
Registration Strip Icon for tools Level up your trading with our powerful tools and real-time insights all in one place.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. Canada
  5. CSE
  6. Defence Therapeutics Inc (DTC)

  7. Defence Therapeutics Inc (DTC) News

DTC

Defence Therapeutics (DTC)

Defence Therapeutics Inc
Date:
Sort by:
 Showing the most relevant articles for your search:CSE:DTC
DateTimeSourceHeadlineSymbolCompany
02/16/20229:00AMInvestorsHub NewsWireDEFENCE RETAINS CATO SMS TO ADVISE ON ITS  PHASE I CLINICAL TRIAL ON ACCUTOXTM FOR BREAST CANCERCSE:DTCDefence Therapeutics Inc
01/26/20227:49AMInvestorsHub NewsWireDefence's AccumTM-HPV vaccine formulation (AccuVAC-PT009) activates a 36-fold higher humoral response compared to Gardasil-9CSE:DTCDefence Therapeutics Inc
11/30/202111:32AMInvestorsHub NewsWireDEFENCE THERAPEUTICS VACCINES AND PROGRAM DEVELOPMENTCSE:DTCDefence Therapeutics Inc
11/23/20217:24AMInvestorsHub NewsWireDEFENCE THERAPEUTICS CANCER VACCINE ACCUVAC-D001 MANUFACTURING TARGETS MELANOMA AND BREAST CANCERCSE:DTCDefence Therapeutics Inc
11/09/202110:50AMInvestorsHub NewsWireDEFENCE THERAPEUTICS APPOINTS DR. RIAM SHAMMAA TO ITS BOARD OF DIRECTORSCSE:DTCDefence Therapeutics Inc
11/03/20217:11AMInvestorsHub NewsWireVACCINE RESULTS: DEFENCE THERAPEUTICS REPORTS SUCCESSFUL COMPLETION OF ITS COVID-19 VACCINE ACCUVAC-PT001 TOXICOLOGY STUDIES IN RABBITSCSE:DTCDefence Therapeutics Inc
10/13/20218:15AMInvestorsHub NewsWireDEFENCE THERAPEUTICS ACCUMTM VARIANTS IN VITRO STUDY INCREASES THE POTENCY OF T-DERUXTECAN ADC BY 5-FOLD ON BREAST CANCERCSE:DTCDefence Therapeutics Inc
10/06/20218:32AMInvestorsHub NewsWireDEFENCE THERAPEUTICS PREPARES FOR PHASE I TRIAL TO TEST ITS DC CANCER VACCINE, ACCUVAC-D002, AGAINST MELANOMACSE:DTCDefence Therapeutics Inc
09/29/20217:30AMInvestorsHub NewsWireDEFENCE THERAPEUTICS TO FINALIZE ITS OBJECTIVES TO INITIATE A PHASE I TRIAL AGAINST BREAST CANCERCSE:DTCDefence Therapeutics Inc
09/20/20219:01AMInvestorsHub NewsWireDEFENCE THERAPEUTICS SUCCESSFULLY ENGINEERED AND TESTED A NOVEL INTRANASAL COVID-19 VACCINE FORMULATION IN ANIMALSCSE:DTCDefence Therapeutics Inc
09/14/20217:13AMInvestorsHub NewsWireDEFENCE THERAPEUTICS SUCCESS IN TESTING IT'S COVID-19 ACCUVAC-PT001 VACCINE IN A NON-RODENT MODELCSE:DTCDefence Therapeutics Inc
09/07/20216:35AMInvestorsHub NewsWireDEFENCE THERAPEUTICS DEVELOPMENT PROGRAM TO ENGINEER A NEW HPV VACCINE INITIATEDCSE:DTCDefence Therapeutics Inc
09/01/20219:39AMInvestorsHub NewsWireThe vaccination specialist is about to become popularCSE:DTCDefence Therapeutics Inc
 Showing the most relevant articles for your search:CSE:DTC

Your Recent History

USOTC
IDVV
International Endeavors (PK)
USOTC
ITUP
Interups (CE)
USOTC
KBLB
Kraig Biocraft Laborator... (QB)
USOTC
MGON
Megola (PK)
USOTC
HIRU
Hiru (PK)
USOTC
ECSL
Ecare Solutions (PK)
USOTC
NBRI
North Bay Resources (PK)
USOTC
VPLM
Voip Pal Com (QB)
USOTC
BIEL
Bioelectronics (PK)
USOTC
CNNA
Cann American (CE)
NASDAQ
LWLG
Lightwave Logic
USOTC
SPZI
Spooz (PK)
USOTC
AABB
Asia Broadband (PK)
USOTC
RONN
Ronn Motor (PK)
USOTC
FNMA
Fannie Mae (QB)
USOTC
SHMP
NaturalShrimp (QB)
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Canada
Company
Business
Popular
Get The App
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved